ArticleCells2026

Development of a Doxorubicin Resistance Model in HER2- and HER2+ Breast Cancer to Analyze Potential Therapy Targets and Drug Delivery Methods.

Sara Molenda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.